microbiolog
play
import
role
practic
medicin
nanodiagnost
refin
detect
infecti
diseas
mani
new
nanotechnologybas
therapi
particularli
viral
diseas
develop
nanobiotechnolog
base
molecular
diagnost
techniqu
describ
chap
exampl
specif
applic
detect
infecti
agent
given
chapter
sever
nanotechnologybas
method
alreadi
describ
chap
includ
ferrofluid
magnet
nanoparticl
ceram
nanospher
nanowir
sensor
virus
role
cantilev
swcnt
qd
surfac
enhanc
raman
scatter
ser
describ
section
microfabr
applic
array
silicon
cantilev
beam
microreson
sensor
nanoscal
thick
appli
detect
mass
individu
viru
particl
dimens
fabric
cantilev
beam
rang
length
width
nm
thick
frequenc
spectra
cantilev
beam
due
thermal
ambient
nois
measur
use
laser
doppler
vibromet
ambient
condit
chang
reson
frequenc
function
viru
particl
mass
bind
cantilev
beam
surfac
form
basi
detect
scheme
devic
detect
singl
vaccinia
viru
particl
averag
mass
fg
devic
use
compon
biosensor
detect
airborn
viru
particl
technolog
refin
describ
nanocantilev
biosensor
singlewal
cnt
swcnt
function
ambient
condit
either
knob
protein
domain
adenoviru
serotyp
ad
knob
human
cellular
receptor
car
protein
via
diimideactiv
amid
biolog
activ
knob
protein
immobil
nanotub
surfac
confirm
use
label
conjug
antibodi
activ
specif
bound
car
swcnt
evalu
first
presenc
fluoresc
label
knob
interact
specif
car
second
neg
control
protein
yief
recogn
biolog
activ
car
protein
addit
currentg
voltag
measur
dozen
nanotub
devic
explor
effect
protein
bind
intrins
electron
properti
swcnt
demonstr
devic
high
sensit
detect
protein
activ
data
show
knob
car
immobil
swcnt
surfac
fulli
retain
biolog
activ
suggest
swcntcar
complex
serv
biosensor
detect
environment
adenovirus
virus
rang
nm
size
although
establish
method
pcr
viru
isol
nextgener
sequenc
ng
use
detect
virus
field
sampl
low
viru
count
pose
major
challeng
viru
surveil
discoveri
uniqu
cnt
sizetun
enrich
microdevic
cntstem
effici
enrich
concentr
virus
collect
field
sampl
yeh
et
al
channel
sidewal
microdevic
made
grow
array
vertic
align
nitrogendop
multiwal
cnt
nmwcnt
intertubular
distanc
cnt
could
engin
rang
nm
accur
match
size
differ
virus
adjust
iron
catalyst
thick
intertubular
distanc
nmwcnt
adjust
snag
trap
virus
cntstem
significantli
improv
detect
limit
viru
isol
rate
least
time
use
devic
author
success
identifi
emerg
avian
influenza
viru
strain
shown
fig
devic
use
low
handl
viral
titer
sampl
fill
contamin
viru
sampl
purifi
research
transport
seal
devic
lab
analysi
ng
pcr
elisa
test
rapid
detect
virus
biolog
sampl
increas
interest
particularli
recent
emerg
new
virus
devic
quickli
easili
detect
difficult
construct
viral
particl
present
low
concentr
biolog
sampl
blood
typic
procedur
involv
use
passiv
diffus
get
viral
particl
bind
antibodi
slow
process
feasibl
mani
applic
battlefield
quick
result
critic
howev
liquid
crystal
known
amplifi
signal
low
concentr
viral
particl
quickli
indic
viru
present
surfac
studi
speed
collect
viral
particl
particularli
vesicular
stomat
viru
use
direct
assembl
extern
electr
fluid
flow
field
design
drive
nanoparticl
specif
locat
specif
concentr
substrat
docosli
et
al
electr
field
advantag
design
electrod
certain
way
engin
control
direction
intens
electr
forc
act
nanoparticl
use
electrod
separ
micromet
togeth
electrotherm
induc
fluid
flow
one
acceler
transport
viral
particl
aqueou
suspens
physiolog
ionic
strength
specif
point
surfac
allow
reach
local
concentr
high
enough
enabl
subsequ
rapid
detect
observ
provid
potenti
use
approach
address
bottleneck
develop
devic
allow
rapid
sampl
onthespot
detect
infecti
biolog
agent
virus
respiratori
syncyti
viru
rsv
caus
one
million
death
annual
worldwid
rsv
mediat
seriou
lower
respiratori
tract
ill
infant
young
children
signific
pathogen
elderli
immun
compromis
although
lifethreaten
one
case
everi
infect
virtual
children
time
year
old
approxim
children
hospit
rsv
us
year
children
us
die
rsv
caus
death
annual
among
elderli
rapid
sensit
rsv
diagnosi
import
infect
control
effort
develop
antivir
drug
current
rsv
detect
method
limit
sensit
andor
time
requir
detect
take
day
delay
effect
treatment
antibodyconjug
nanoparticl
rapidli
sensit
detect
rsv
estim
rel
level
surfac
protein
express
major
develop
use
dualcolor
qd
fluoresc
energi
transfer
nanobead
simultan
excit
singl
light
sourc
qd
system
detect
presenc
particl
rsv
matter
hour
also
sensit
allow
detect
viru
earlier
infect
rsv
viru
infect
lung
cell
leav
part
coat
contain
f
g
protein
cell
surfac
qd
link
antibodi
key
structur
uniqu
rsv
coat
therefor
qd
come
contact
either
viral
particl
infect
cell
stick
surfac
addit
coloc
viral
protein
shown
use
confoc
microscopi
potenti
benefit
earli
detect
system
increas
proper
use
antivir
medicin
although
medicin
develop
respiratori
virus
use
often
therapi
effect
given
earli
cours
infect
time
current
test
identifi
viru
gener
late
work
reduc
inappropri
use
antibiot
current
physician
often
prescrib
antibiot
respiratori
ill
howev
antibiot
combat
respiratori
ill
caus
bacteria
ineffect
viral
infect
earli
viru
detect
method
would
reduc
frequenc
doctor
prescrib
antibiot
viral
infect
inappropri
therebi
reduc
unnecessari
antibiot
sideeffect
cut
develop
antibioticresist
bacteria
allow
hospit
personnel
isol
rsv
patient
rsv
extrem
infecti
earli
detect
would
allow
hospit
personnel
keep
rsv
patient
separ
patient
especi
suscept
infect
undergo
bonemarrow
transplant
current
three
diagnost
test
avail
identifi
respiratori
virus
like
rsv
gold
standard
involv
incub
infect
sampl
tissu
cultur
day
use
fluoresc
dye
test
presenc
viru
main
problem
techniqu
viru
multipli
patient
time
grow
cultur
caus
mani
hospit
switch
real
time
pcr
extrem
sensit
still
take
sever
hour
need
technician
well
train
molecular
biologist
conduct
test
refer
laboratori
third
method
antigen
test
take
min
sensit
enough
detect
presenc
viru
earli
stage
infect
comparison
qd
method
take
h
even
sensit
real
time
pcr
detect
presenc
rsv
within
hour
viru
ad
cultur
qd
advantag
mani
tradit
fluorophor
fluoresc
properti
fine
tune
resist
photobleach
halfpenni
wright
verigen
nanospher
inc
platform
base
direct
genom
detect
technolog
use
dna
probe
coat
gold
nanoparticl
identifi
uniqu
oligonucleotid
sequenc
combin
biobarcod
protein
detect
technolog
verigen
respiratori
viru
plu
assay
run
autom
sampletoresult
molecular
diagnost
instrument
sensit
current
avail
rapid
test
combin
optim
eas
use
turnaround
time
found
either
tradit
cultur
method
current
avail
molecular
test
virus
clear
fda
detect
influenza
rsv
although
surfac
enhanc
raman
scatter
ser
well
known
previou
attempt
use
spectroscopi
diagnos
virus
fail
signal
produc
inher
weak
spectroscop
assay
base
ser
use
silver
nanorod
significantli
amplifi
signal
develop
rapid
detect
trace
level
virus
high
degre
sensit
specif
shanmukh
et
al
techniqu
measur
chang
frequenc
nearinfrar
laser
scatter
viral
dna
rna
chang
frequenc
distinct
fingerprint
novel
ser
assay
detect
spectral
differ
virus
viral
strain
virus
gene
delet
biolog
media
method
provid
rapid
diagnost
min
detect
character
virus
gener
reproduc
spectra
without
viral
manipul
also
quit
cheap
reproduc
dualmod
molecular
beacon
base
combin
ser
fluoresc
molecular
beacon
assay
assembl
nanobarcod
particl
develop
use
measur
unlabel
human
viral
rna
sha
et
al
molecular
beacon
probe
singlestrand
oligonucleotid
design
hairpin
structur
hold
dye
close
particl
surfac
probe
attach
group
configur
ser
spectrum
label
obtain
fluoresc
quench
dye
close
nobl
metal
surfac
nanoscal
featur
ser
signal
decreas
fluoresc
signal
increas
target
viral
rna
captur
molecular
beacon
probe
addit
hcv
rtpcr
product
detect
use
dualmod
beacon
develop
multiplex
labelfre
assay
system
reassur
offer
detect
two
distinctli
separ
signal
offer
signific
benefit
rapid
molecular
diagnost
rapid
sensit
detect
pathogen
bacteria
extrem
import
diagnosi
infect
poc
limit
convent
diagnost
method
lack
ultrasensit
delay
get
result
nanobiotechnolog
made
signific
contribut
improv
detect
bacteri
infect
bioconjug
nanoparticlebas
assay
situ
pathogen
quantif
detect
singl
bacterium
within
minut
nanoparticl
provid
high
fluoresc
signal
bioanalysi
easili
incorpor
biorecognit
molecul
antibodi
antibodyconjug
nanoparticl
readili
specif
identifi
varieti
bacteria
escherichia
coli
antibodyantigen
interact
recognit
method
appli
multipl
bacteri
sampl
high
throughput
potenti
applic
ultrasensit
detect
diseas
biomark
infecti
agent
verigen
gramposit
blood
cultur
bcgp
test
nanospher
inc
multiplex
nanoparticlebas
autom
nucleic
acid
test
identif
genu
speci
genet
resist
determin
broad
panel
common
gramposit
blood
cultur
isol
wherea
convent
microbiolog
method
may
requir
day
produc
bacteri
identif
resist
result
verigen
bcgp
test
provid
result
within
h
blood
cultur
posit
verigen
system
uniqu
instrument
min
user
handson
time
per
test
enabl
true
random
access
test
process
directli
posit
blood
cultur
bottl
multifunct
magneticplasmon
fe
au
coreshel
nanoparticl
aumnp
prepar
simultan
fast
concentr
bacteri
cell
appli
extern
point
magnet
field
sensit
detect
identif
bacteria
use
ser
zhang
et
al
surround
dens
uniformli
pack
aumnp
bacteria
sensit
reproduc
detect
directli
use
ser
method
use
molecular
diagnosi
bacteri
infect
aunp
function
singl
strand
oligonucleotid
visual
detect
probe
aunpoligo
probe
use
rapid
specif
detect
e
coli
padmavathi
et
al
aunpoligo
probe
hybrid
target
dna
sampl
contain
complementari
sequenc
remain
red
wherea
test
sampl
without
complementari
dna
sequenc
probe
turn
purpl
due
acid
induc
aggreg
aunpoligo
probe
color
chang
solut
observ
visual
nake
eye
demonstr
direct
rapid
detect
pathogen
e
coli
genom
dna
without
need
pcr
amplif
limit
detect
ng
unamplifi
genom
dna
method
requir
complet
genom
dna
extract
howev
use
unamplifi
enzymat
digest
genom
dna
detect
limit
ng
attain
result
uvvi
spectroscop
measur
afm
imag
support
feasibl
aggregationbas
visual
discrimin
assay
valid
clinic
specimen
pathogen
e
coli
obtain
local
hospit
found
sensit
well
highli
specif
without
cross
reaction
nonescherichia
coli
strain
salient
featur
approach
includ
poc
applic
lowcost
robust
reagent
simpl
colorimetr
detect
pathogen
detect
singlemolecul
hybrid
achiev
hybrid
detect
method
use
multicolor
oligonucleotidefunction
qd
nanoprob
presenc
variou
target
sequenc
combinatori
selfassembl
nanoprob
via
independ
hybrid
reaction
lead
gener
discern
sequencespecif
spectral
code
method
use
genet
analysi
anthrax
pathogen
simultan
detect
multipl
relev
sequenc
fluoresc
qd
coat
zinc
ii
dipicolylamin
coordin
complex
select
stain
rough
e
coli
mutant
lack
oantigen
element
permit
optic
detect
live
mous
leg
infect
model
leevi
et
al
qd
potenti
use
label
agent
bacteriophag
associ
bacteri
infect
rapid
simpl
method
report
combin
vivo
biotinyl
engin
hostspecif
bacteriophag
conjug
phage
streptavidinco
qd
edgar
et
al
method
provid
specif
detect
bacteri
cell
per
ml
experiment
sampl
approxim
amplif
signal
background
h
method
appli
bacteria
suscept
specif
phage
would
particularli
use
detect
bacteri
strain
slow
grow
mycobacterium
highli
infecti
b
anthraci
monitor
infect
e
coli
cell
light
microscopi
procedur
develop
tag
matur
bacteriophag
qd
edgar
et
al
fluoresc
qd
use
detect
sort
pathogen
bacteria
flowcytometri
zahavi
et
al
convent
method
diagnosi
invas
fungal
infect
clinic
microbiolog
laboratori
timeconsum
process
result
misidentif
fungu
due
low
sensit
low
specif
need
improv
method
detect
fungi
nanobiotechnologybas
techniqu
use
magnet
reson
detect
biosystem
use
magnet
nanoparticl
coupl
reagent
quickli
detect
within
minut
presenc
specif
substanc
solut
use
miniatur
portabl
mri
instrument
detect
high
intens
mri
signal
solut
enabl
detect
low
concentr
target
agent
substanc
unlik
exist
diagnost
detect
techniqu
base
optic
detect
method
requir
pure
sampl
multipl
process
step
technolog
optic
therefor
requir
purif
biolog
sampl
signific
advantag
allow
system
perform
singlestep
process
rapid
turnaround
time
without
need
train
technician
furthermor
technolog
accur
identifi
almost
specimen
includ
protein
nucleic
acid
enzym
microb
small
molecul
drug
compound
within
almost
sampl
includ
whole
blood
plasma
serum
urin
method
use
analyz
whole
blood
specimen
patient
five
differ
type
candida
spp
infect
current
clinic
trial
aim
regulatori
approv
diagnosi
candida
infect
one
method
fungal
ribosom
dna
amplifi
use
pcr
product
hybrid
speciesspecif
probe
immobil
surfac
microarray
hybrid
signal
enhanc
gold
nanoparticl
silver
deposit
lu
et
al
probe
design
detect
sever
differ
clinic
pathogen
fungi
use
flatb
scanner
visual
techniqu
show
higher
effici
specif
sensit
compar
method
nanobacteria
mineralform
sterilefilter
slowgrow
gramneg
infecti
agent
detect
bovinehuman
blood
urin
nanobacterialik
particl
detect
synovi
fluid
arthriti
patient
shown
gradual
increas
number
size
cultur
tsurumoto
et
al
nanobacteria
implic
varieti
human
diseas
associ
patholog
calcif
remark
characterist
format
carbon
apatit
crystal
neutral
ph
physiolog
phosphat
calcium
concentr
extracellular
miner
form
hardprotect
shelter
hardi
microorgan
enabl
surviv
condit
physic
stress
would
lethal
bacteri
speci
olavi
kajand
group
finland
suggest
apatit
produc
nanobacteria
may
play
key
role
format
kidney
stone
provid
central
calcium
phosphat
deposit
around
crystallin
compon
collect
nanobacteria
seem
caus
agent
diseas
relat
biominer
process
nanobacteria
also
associ
calcifi
geolog
specimen
human
kidney
stone
psammona
bodi
ovarian
cancer
much
research
focus
attent
potenti
role
particl
may
play
develop
urolog
patholog
includ
polycyst
kidney
diseas
renal
calculi
chronic
prostat
nanobacteria
may
import
etiolog
factor
type
iii
prostat
reproduc
rat
prostat
infect
model
infus
nanobacteria
suspens
transurethr
shen
et
al
recent
clinic
research
agent
target
nanobacteria
proven
effect
treat
patient
refractori
categori
iii
prostat
accord
rdna
structur
nanobacteria
belong
proteobacteria
subgroup
includ
brucella
bartonella
speci
nanobacterium
sanguineum
nanobacteria
smallest
selfrepl
organ
ever
detect
billionth
meter
size
smallest
previous
known
bacteria
primordi
protein
nanobacteria
recent
identifi
atmospher
could
play
signific
role
cloud
acceler
format
cloud
droplet
interconnect
nanobacteria
possibl
nanobacteria
microorgan
thu
enhanc
chanc
eventu
reach
earth
sever
research
studi
indic
nanobacteria
aliv
still
unclear
whether
repres
novel
life
form
overlook
nanometers
bacteria
primit
selfrepl
microorgan
studi
shown
caco
precipit
prepar
vitro
remark
like
purport
nanobacteria
term
uniformli
size
membranedelin
vesicular
shape
cellular
divisionlik
format
aggreg
form
coloni
martel
young
gradual
appear
nanobacterialik
particl
incub
human
serum
well
chang
seen
size
shape
influenc
explain
introduc
vari
level
co
nahco
well
condit
known
influenc
precipit
caco
western
blot
reveal
monoclon
antibodi
claim
specif
nanobacteria
react
fact
serum
albumin
furthermor
nanobacterialik
particl
obtain
human
blood
withstand
high
dose
irradi
kgi
bacteri
dna
found
perform
broadrang
pcr
amplif
find
provid
plausibl
abiot
explan
unusu
properti
purport
nanobacteria
approxim
men
women
develop
kidney
stone
time
reach
age
year
exactli
kidney
stone
form
known
kidney
stone
debilit
recur
patient
within
year
kidney
stone
format
multifactori
diseas
defens
mechan
risk
factor
imbalanc
favor
stone
format
one
theori
nanoparticl
accumul
kidney
form
focu
subsequ
growth
larger
stone
month
year
factor
physic
chemistri
protein
inhibitor
crystal
growth
also
play
role
miner
form
nanobacteria
activ
nidi
attach
invad
damag
urinari
epithelium
collect
duct
papilla
form
calcium
phosphat
center
found
kidney
stone
scientist
nasa
use
multipl
techniqu
determin
nanobacteria
infect
multipli
faster
space
flight
simul
condit
earth
nanobacteria
consid
initi
kidney
stone
format
grow
faster
micrograv
environ
may
explain
astronaut
get
kidney
stone
space
mission
discoveri
may
prove
critic
futur
exploratori
mission
moon
mar
proof
hypothesi
screen
nanobacteri
antigen
antibodi
level
flight
crew
flight
would
necessari
concept
also
open
door
new
diagnost
therapeut
techniqu
address
nanobacteri
infect
kidney
stone
nanoparticl
isol
cultur
renal
stone
obtain
time
surgic
resect
kumar
et
al
isol
suscept
select
metabol
inhibitor
antibiot
contain
conserv
bacteri
protein
dna
result
suggest
renal
stone
format
unlik
driven
sole
physic
chemistri
rather
critic
influenc
specif
protein
cellular
respons
understand
event
provid
clue
toward
novel
therapeut
target
use
highspati
energi
resolut
nearedg
xray
absorpt
fine
structur
nm
spatial
scale
possibl
defin
biochem
signatur
cultur
calcifi
bacteria
includ
protein
polysaccharid
nucleic
acid
hydroxyapatit
benzerara
et
al
preliminari
studi
suggest
nanoparticl
isol
human
sampl
share
spectroscop
characterist
calcifi
protein
nanometerscal
object
spheric
shape
rang
size
nm
spectral
pattern
calcium
phosphoru
highenergi
dispers
spectroscopi
identifi
posit
immunostain
surgic
specimen
patient
cardiovascular
patholog
nanos
particl
cultur
calcifi
noncalcifi
aneurysm
recogn
dnaspecif
dye
incorpor
radiolabel
uridin
decalcif
appear
via
electron
microscopi
contain
cell
wall
nanometerscal
particl
like
describ
nanobacteria
isol
geolog
specimen
human
kidney
stone
visual
cultur
human
calcifi
cardiovascular
tissu
studi
nanoparticl
found
near
plaquefil
arteri
anim
model
observ
suggest
nanoparticl
potenti
repres
previous
unrecogn
factor
develop
arteriosclerosi
calcif
arteri
diseas
cnt
potenti
address
challeng
combat
infecti
agent
minim
toxic
dose
reduct
standard
therapeut
allow
multipl
payload
capac
achiev
target
activ
combat
infecti
strain
particularli
resist
antibiot
rosen
elman
one
uniqu
characterist
network
carbon
atom
nanomet
scale
allow
creation
nanochannel
via
cellular
membran
attempt
made
destroy
anthrax
spore
antimicrobi
agent
target
bind
carbohydr
spore
surfac
limit
success
swcnt
success
use
truli
uniqu
scaffold
display
multival
monosaccharid
ligand
bind
effect
anthrax
spore
dival
cation
mediat
caus
signific
spore
aggreg
wang
et
al
work
farreach
implic
develop
technolog
counteract
bioterror
use
anthrax
swcnt
effect
anthrax
must
made
fine
powder
easili
enter
lung
inhal
nanotechnologybas
agent
cling
anthrax
spore
make
inhal
lung
difficult
similar
approach
use
sugarco
carbon
nanotub
stop
spread
e
coli
bacteria
test
success
colloid
silver
use
antibacteri
agent
sinc
ancient
greec
unlik
antibiot
drug
bacteria
easili
develop
resist
silver
target
multipl
compon
bacteri
cell
effect
gold
silver
np
investig
bcg
e
coli
zhou
et
al
experiment
particl
size
shape
character
use
tem
differ
concentr
np
appli
bacteri
cultur
growth
e
coli
monitor
coloni
form
unit
cfu
mechan
interact
np
bacteria
analyz
bacteri
thin
section
follow
tem
sem
antibacteri
effect
bcg
observ
record
fluoresc
protein
express
level
result
suggest
np
potenti
applic
antitb
compound
antibacteri
effect
mechan
action
np
depend
upon
composit
surfac
modif
syntheticpeptid
contain
arginin
tryptophan
cystein
target
negativelycharg
bacteria
penetr
bacteri
cell
membran
peptid
immobil
gold
nanoparticl
aunp
shown
target
capac
antibacteri
activ
staphylococci
enterococci
antibioticresist
bacteri
strain
kuo
et
al
address
problem
antibiot
drug
resist
studi
use
aureu
proofofprincipl
pathogen
demonstr
appropri
antibiot
daptomycin
incorpor
polydopamineco
gold
nanocag
aunc
pda
conjug
antibodi
target
speciesspecif
surfac
protein
staphylococc
protein
spa
mean
achiev
select
deliveri
nanoconstruct
directli
bacteri
cell
surfac
meeker
et
al
target
specif
confirm
demonstr
lack
bind
mammalian
cell
reduc
phototherm
antibiot
kill
spaneg
speci
staphylococcu
epidermidi
reduc
kill
aureu
presenc
unconjug
antispa
antibodi
author
demonstr
laser
irradi
level
within
current
safeti
standard
use
human
use
achiev
lethal
phototherm
effect
control
releas
antibiot
thu
result
degre
therapeut
synergi
capabl
erad
viabl
aureu
cell
system
valid
use
plankton
bacteri
cultur
methicillinsensit
methicillinresist
aureu
strain
approach
potenti
expand
deal
bacteri
pathogen
could
target
substitut
effect
antibiot
appropri
target
agent
antibodi
peptid
etc
thu
concept
use
photoactivat
nanodrug
tremend
potenti
overcom
grow
problem
acquir
antibiot
resist
bacteria
well
intrins
resist
biofilmassoci
infect
meeker
et
al
antimicrobi
peptid
natur
weapon
bacteria
bodi
occur
mani
organ
offer
possibl
altern
convent
antibiot
increas
resist
convent
antibiot
yet
success
use
clinic
broken
human
bodi
quickli
exert
effect
effort
made
develop
liquidcrystallin
nanocarri
protect
peptid
thu
ensur
safe
deliv
target
site
smallangl
xray
scatter
dynam
light
scatter
cryogen
transmiss
electron
microscopi
studi
shown
amphiphil
peptid
integr
bicontinu
cubic
structur
induc
colloid
transform
micel
concentrationdepend
manner
gontsarik
et
al
investig
along
vitro
evalu
studi
use
clinic
relev
bacteri
strain
determin
compositionnanostructureact
relationship
guid
design
new
nanocarri
antimicrobi
peptid
may
provid
essenti
knowledg
mechan
underli
bacteri
membran
disrupt
peptideload
nanostructur
protect
cover
form
lipid
ensur
safe
deliveri
peptid
area
need
also
intensifi
action
target
site
structur
nanocarri
may
modifi
way
enabl
control
releas
specif
time
topic
research
antimicrobi
nanoemuls
nanobio
emuls
contain
water
soya
bean
oil
uniformli
size
droplet
nm
rang
droplet
stabil
surfact
respons
microbicid
activ
concentr
form
nanoemuls
appear
white
milki
substanc
tast
consist
cream
formul
varieti
carrier
allow
gel
cream
liquid
product
etc
applic
nanoemuls
becom
larg
waterbas
case
beverag
preserv
compris
less
result
mixtur
laboratori
result
indic
shelf
life
least
year
virtual
toxic
nanobio
corpor
nanoemuls
destroy
microb
effect
without
toxic
harm
residu
effect
nanoparticl
fuse
membran
microb
surfact
disrupt
membran
kill
microb
class
microb
erad
viru
eg
hiv
herp
bacteria
eg
e
coli
salmonella
spore
eg
anthrax
fungi
eg
candida
albican
byssochlami
fulva
nanobio
nanoemuls
antimicrobi
agent
treatment
infect
due
cfrelat
opportunist
pathogen
develop
see
chapter
nanopulmonolog
clinic
trial
shown
efficaci
heal
cold
sore
due
herp
simplex
viru
toenail
fungu
nanoemuls
also
formul
kill
one
two
class
microb
due
larg
part
low
toxic
profil
nanoemuls
platform
technolog
number
topic
oral
vagin
cutan
preserv
decontamin
veterinari
agricultur
antimicrobi
applic
sinc
nontox
noncorros
nanoemuls
use
decontamin
personnel
equip
terrain
structur
water
test
dtra
defens
threat
reduct
agenc
agenc
us
depart
defens
demonstr
nanoemuls
chemic
decontamin
agent
us
armi
test
nanoemuls
nine
biodecontamin
technolog
anthrax
surrog
nanoemuls
one
four
technolog
prove
effect
antibiot
resist
bacteria
caus
local
acid
phenomenon
occur
due
combin
action
bacteri
metabol
host
immun
respons
np
shown
promis
treat
bacteri
infect
signific
challeng
develop
formul
may
suitabl
system
administr
drugencapsul
phrespons
surfac
chargeswitch
poli
llacticcoglycol
acid
bpoli
lhistidin
bpoli
ethylen
glycol
plgaplhpeg
nanoparticl
develop
treat
bacteri
infect
radovicmoreno
et
al
antibioticcarri
np
design
switch
charg
depend
environ
circul
bloodstream
particl
slight
neg
charg
howev
encount
infect
site
particl
gain
posit
charg
allow
tightli
bind
bacteria
releas
drug
payload
switch
provok
slightli
acid
environ
surround
bacteria
due
lack
oxygen
trigger
chang
bacteri
metabol
lead
produc
organ
acid
bodi
immun
cell
neutrophil
also
produc
acid
tri
consum
bacteria
np
drug
carrier
design
shield
nontarget
interact
ph
bind
avidli
bacteria
acid
deliv
drug
mitig
part
loss
drug
activ
declin
ph
np
bind
studi
demonstr
phsensit
np
bind
bacteria
increas
bind
bacteria
ph
compar
plgaplhpegencapsul
vancomycin
demonstr
reduc
loss
efficaci
low
ph
increas
minimum
inhibitori
concentr
compar
free
plgapegencapsul
vancomycin
respect
plgaplhpeg
np
first
step
toward
develop
system
administ
drug
carrier
target
potenti
treat
gramposit
gramneg
polymicrobi
infect
associ
acid
approach
would
enabl
target
deliveri
high
dose
antibiot
extend
period
overcom
antibiot
resist
protect
benefici
bacteria
normal
live
insid
human
bodi
potenti
challeng
approach
neg
charg
tissu
cell
protein
infect
site
compet
bacteria
bind
nanoparticl
potenti
block
bind
bacteria
investig
studi
much
might
limit
effect
np
deliveri
also
conduct
studi
anim
determin
whether
particl
remain
phsensit
bodi
surviv
circul
long
enough
reach
target
exampl
nanosom
amphotericin
b
jina
pharmaceut
inc
formul
lipid
without
use
deterg
toxic
organ
solvent
prepar
sheikh
et
al
electron
microscopi
particl
size
determin
prepar
show
homogen
popul
nanos
particl
nm
hemolysi
assay
indic
nanosom
amphotericin
b
caus
significantli
less
lysi
red
blood
cell
amphotericin
b
deoxychol
compar
ambisom
approv
liposom
prepar
maximum
daili
dose
nanosom
amphotericin
b
mgkg
rabbit
mgkg
mice
day
show
symptom
toxic
mortal
signific
bodi
weight
reduct
nanosom
amphotericin
b
ambisom
inject
intraven
mgkg
consecut
day
mice
infect
aspergillu
fumigatu
treatment
result
surviv
nanosom
amphotericin
b
surviv
ambisom
day
fungal
infect
howev
control
mice
treat
amphotericin
b
die
within
day
fungal
infect
nanosom
amphotericin
b
safe
costeffect
provid
altern
option
treatment
fungal
diseas
certain
formul
nanoscal
powder
possess
antimicrobi
properti
formul
made
simpl
nontox
metal
oxid
magnesium
oxid
mgo
calcium
oxid
cao
lime
nanocrystallin
form
carri
activ
form
halogen
eg
mgocl
mgobr
ultrafin
powder
contact
veget
cell
escherichia
coli
bacillu
cereu
bacillu
globigii
kill
within
minut
likewis
spore
form
bacillu
speci
decontamin
within
sever
hour
dri
contact
aflatoxin
contact
bacteriophag
surrog
human
enteroviru
water
also
caus
decontamin
minut
nanopowd
mgo
scour
contamin
room
anthrax
spore
unlik
antibacteri
gase
foam
messi
corros
ruin
electr
equip
powder
spray
room
swept
vacuum
chemic
speck
attract
opposit
charg
spore
particl
chemic
break
spore
tough
outer
shell
base
technolog
nanoscal
corpor
market
dri
powder
dub
first
appli
sorbent
treatment
chemic
threat
decompos
toxic
chemic
powder
contain
reactiv
nanoparticl
attract
break
least
commonli
transport
toxic
chemic
includ
acid
unlik
foam
powder
need
wet
effect
work
liquid
vapor
simpl
molecul
synthes
hydrocarbon
ammonium
compound
produc
uniqu
nanotub
structur
antimicrobi
capabl
quaternari
ammonium
compound
known
abil
disrupt
cell
membran
caus
cell
death
wherea
hydrocarbon
diacetylen
chang
color
appropri
formul
result
molecul
would
desir
properti
biosensor
biocid
selfassembl
nanotub
perfectli
uniform
organ
expans
upright
cluster
magnifi
million
time
resembl
fiber
shag
rug
lead
name
nanocarpet
selfassembl
nanotub
diamet
nm
wall
thick
nm
nanocarpet
measur
height
approxim
height
freeform
nanotub
align
nanotub
absenc
templat
unpreced
repres
import
step
toward
ration
design
bioactiv
nanostructur
addit
form
within
hour
roomtemperatur
condit
signific
cost
synthes
carbon
nanotub
reduc
normal
neutral
color
expos
ultraviolet
light
nanotub
chang
perman
deep
blue
process
also
chemic
alter
nanotub
becam
polymer
give
firmer
structur
polymer
nanotub
could
chang
blue
color
depend
exposur
differ
materi
instanc
test
acid
deterg
turn
red
yellow
display
sensit
differ
agent
chang
color
nanotub
train
kill
bacteria
presenc
e
coli
strain
foodborn
pathogen
nanotub
turn
shade
red
pink
moreov
aid
electron
microscop
research
observ
tube
pierc
membran
bacteria
like
needl
insert
cell
polymer
chang
color
unpolymer
nanotub
structur
effect
antimicrobi
complet
kill
e
coli
within
hour
time
find
implic
develop
product
simultan
detect
kill
biolog
weapon
research
fund
depart
defens
armi
research
offic
goal
develop
paint
event
biolog
chemic
agent
deploy
would
chang
color
simultan
destroy
deadli
substanc
first
natur
surfac
found
kill
bacteria
simpli
physic
structur
array
hexagon
nanopillar
wing
clanger
cicada
psaltoda
claripenni
put
enough
strain
bacteri
cell
ruptur
pogodin
et
al
nanopillar
punctur
bacteria
stick
tip
nanopillar
stretch
hexagon
space
put
extrem
strain
cell
nanoscal
defens
appear
work
bacteria
rel
soft
membran
greater
membran
rigid
could
surviv
stretch
pillar
howev
decreas
rigid
surfaceresist
strain
microwav
irradi
cell
render
suscept
wing
effect
find
provid
new
strategi
antibacteri
prophylaxi
common
sourc
transmiss
bacteri
infect
public
rail
design
mimic
nanopillar
provid
antibacteri
surfac
silver
use
medic
equip
coat
dental
resin
compon
mechan
underli
antibacteri
activ
weaken
dna
replic
inactiv
protein
institut
new
materi
saarbrucken
germani
research
institut
special
appli
nanotechnolog
applic
develop
silver
nanoparticl
surfac
coat
deadli
fungi
bacteria
research
ad
germicid
abil
sprinkl
copiou
amount
silver
nanoparticl
coat
materi
everi
squar
centimet
contain
one
billion
invis
particl
align
releas
tini
number
silver
ion
ion
death
knell
fungu
bacteria
might
succeed
gather
surfac
despit
alreadi
dirtrepel
qualiti
applic
includ
surfac
germ
gather
possibl
endang
peopl
health
includ
surfac
hospit
public
build
factori
home
coat
could
appli
almost
surfac
peopl
touch
often
metal
glass
plastic
would
remov
need
constant
clean
liquid
disinfect
especi
area
hygien
condit
crucial
peopl
normal
use
hear
aid
lie
insid
ear
risk
infect
auditori
canal
safe
wear
nanoco
applianc
biogat
germani
produc
nanosilv
bg
nanopor
silver
powder
particl
size
rang
nm
nm
homogen
distribut
nanoparticl
materi
antiinfect
properti
silver
nanoparticl
incorpor
prepar
wound
care
prevent
infect
acticoat
bandag
smith
nephew
contain
nanocryst
silver
highli
toxic
pathogen
wound
acrym
silver
nanoparticl
technolog
silvagard
involv
coat
silver
nanoparticl
size
rang
nm
stabl
solut
antimicrobi
treatment
level
last
year
technolog
nanobas
silver
coat
must
appli
vapor
deposit
coat
one
side
wherea
acrym
technolog
solut
provid
complet
surfac
treatment
rather
coat
scan
surfac
confoc
microscopi
simultan
record
highresolut
topographi
cell
surfac
fluoresc
singl
scan
enabl
imag
individu
fluoresc
particl
nanomet
rang
fix
live
cell
techniqu
use
record
interact
singl
viruslik
particl
cell
surfac
demonstr
singl
particl
sink
membran
invagin
reminisc
pinocyt
vesicl
method
enabl
elucid
interact
individu
virus
nanoparticl
gene
therapi
vector
target
cell
silver
nanoparticl
undergo
sizedepend
interact
particl
rang
nm
attach
viru
regular
spatial
arrang
attach
nanoparticl
centertocent
distanc
nanoparticl
fact
expos
sulfurbear
residu
glycoprotein
knob
would
attract
site
nanoparticl
interact
suggest
silver
nanoparticl
interact
viru
via
preferenti
bind
glycoprotein
knob
due
interact
silver
nanoparticl
inhibit
viru
bind
host
cell
demonstr
vitro
research
nanobiotechnolog
help
understand
pathomechan
viral
diseas
devis
strategi
treatment
exampl
neurotrop
herp
simplex
viru
hsv
infect
mucos
epithelia
enter
nerv
termin
travel
axon
dorsal
root
ganglia
neuron
deliv
genom
nucleu
cell
bodi
nucleu
genom
may
give
rise
infecti
progeni
becom
latent
littl
gene
express
silenc
genom
reactiv
upon
stress
establish
product
infect
peripher
nervou
system
later
also
mucos
peripheri
achiev
viru
must
elud
host
restrict
multipl
level
includ
entri
cytoplasm
transport
replic
innat
adapt
immun
recognit
egress
infect
cell
research
viru
nanoparticl
provid
cue
regul
cytoplasm
transport
virus
replic
genom
nucleu
make
use
microtubul
actin
cytoskeleton
molecular
motor
traffick
toward
nuclear
membran
entri
peripheri
egress
replic
analyz
underli
principl
viral
cytosol
transport
help
design
viral
vector
use
research
well
human
gene
therapi
identif
new
antivir
target
molecul
dermavir
patch
genet
immun
transderm
deliv
nanomedicin
enhanc
de
novo
hivspecif
memori
tcell
respons
hivinfect
individu
improv
abil
immun
system
control
diseas
kill
hivinfect
cell
mice
receiv
dermavir
formul
gag
plasmid
presenc
plasmid
significantli
enhanc
gagspecif
central
memori
tcell
measur
peptidebas
cultur
elispot
calarota
et
al
dermavir
primevaccinia
vector
boost
regimen
inclus
togeth
dermavir
significantli
improv
gagspecif
effector
memori
tcell
respons
studi
demonstr
promis
dermavir
adjuv
enhanc
antigenspecif
central
memori
type
tcell
primeboost
set
phase
ii
clinic
trial
one
complic
blood
transfus
transmiss
viral
infect
nanofiltr
use
nanotechnolog
viral
remov
filtrat
system
import
safeti
step
manufactur
plasmaderiv
coagul
factor
concentr
biopharmaceut
product
human
blood
nanofiltr
plasma
product
alreadi
carri
sinc
earli
improv
margin
viral
safeti
complement
viral
reduct
treatment
solventdeterg
heat
treatment
appli
inactiv
hiv
well
hepat
b
c
virus
main
reason
introduct
nanofiltr
need
improv
product
safeti
nonenvelop
virus
provid
possibl
safeguard
new
infecti
agent
potenti
enter
human
plasma
pool
nanofiltr
gain
quick
accept
rel
simpl
manufactur
step
consist
filter
protein
solut
membran
nanopor
pore
size
typic
nm
condit
retain
virus
mechan
larg
base
size
exclus
recent
largescal
experi
throughout
world
establish
nanofiltr
robust
reliabl
viral
reduct
techniqu
appli
essenti
plasma
product
mani
licens
plasma
product
current
nanofilt
technolog
major
advantag
flexibl
may
combin
effici
larg
predict
remov
wide
rang
virus
compar
viral
reduct
mean
nanofiltr
may
method
date
permit
effici
remov
envelop
nonenvelop
virus
condit
protein
activ
recov
new
data
indic
nanofiltr
may
also
remov
prion
open
new
perspect
develop
techniqu
shortcom
membran
often
form
pinhol
crack
fabric
process
result
wast
membran
special
design
ceram
membran
use
nanomesh
nanofiltr
less
like
damag
manufactur
potenti
remov
virus
water
air
blood
mesh
structur
effici
form
filtrat
success
construct
nanoscal
ceram
fiber
modif
increas
rate
flow
pass
membran
compar
current
ceram
membran
maintain
effici
captur
unwant
particl
technolog
could
use
filter
airborn
virus
sever
acut
respiratori
syndrom
sar
avian
flu
viru
may
possibl
filter
hiv
human
blood
treat
patient
aid
antibodi
typic
neutral
virus
bind
virion
particl
solut
prior
attach
suscept
cell
virus
enter
cell
convent
antibodi
inhibit
viru
infect
replic
method
describ
deliveri
small
recombin
antibodi
fragment
virusinfect
cell
use
dendrimerbas
molecular
transport
sapparapu
et
al
construct
penetr
virusinfect
cell
effici
inhibit
viru
replic
method
provid
novel
approach
immedi
deliveri
inhibitori
antibodi
direct
viru
protein
expos
intracellular
environ
approach
circumv
current
rather
complic
express
inhibitori
antibodi
cell
follow
gene
transfer
intern
via
molecular
transporterantibodi
conjug
reach
conserv
intern
viral
protein
infect
cell
could
expand
use
antibodi
beyond
prophylact
indic
therapeut
applic
novel
antibodi
could
also
coupl
rnai
strategi
combin
antivir
therapi
power
monotherapi
due
synergist
effect
dcbase
immunotherapi
variou
limit
one
critic
point
antigen
load
dc
nanotechnolog
offer
new
tool
overcom
constraint
dendrim
propos
carrier
target
deliveri
hiv
antigen
dc
nanosystem
releas
antigen
control
manner
lead
potent
specif
immun
respons
improv
ration
synthesi
engin
dendrim
well
new
strategi
hiv
epitop
select
antigen
design
overlap
peptid
bioinformaticdesign
mosaic
antigen
immunogen
broadli
neutral
antibodyderiv
peptid
permit
design
novel
safe
immunogen
nanovaccin
effect
target
antigen
deliveri
vivo
replac
expens
unbeat
ex
vivo
cultur
techniqu
facilit
largescal
applic
dcbase
vaccin
et
al
seri
bisfulleropyrrolidin
bear
two
ammonium
group
synthes
activ
evalu
marchesan
et
al
two
tran
isom
found
interest
antivir
properti
confirm
import
rel
posit
substitu
cage
none
compound
show
inhibitori
activ
varieti
dna
rna
virus
hiv
cation
anion
amino
acidtyp
fulleren
deriv
inhibitori
effect
hivrevers
transcriptas
hcv
deriv
fulleren
anion
fulleren
found
activ
tri
fulleren
deriv
activ
nonnucleosid
analog
hivrt
inhibitor
effect
long
alkyl
chain
fulleren
signific
rather
depress
inhibit
strength
two
import
target
antihiv
characterist
hivproteas
hivrevers
transcriptas
molecular
model
experiment
design
exhibit
could
penetr
hydrophob
bind
site
hiv
proteas
howev
mechan
antihiv
activ
hivproteas
inhibit
experiment
demonstr
emerg
pandem
influenza
viru
becom
worldwid
health
concern
drug
resist
appear
new
gener
therapeut
strategi
requir
use
rna
immun
activ
molecul
limit
instabl
deliv
cell
overcom
use
nanobiotechnologybas
deliveri
system
gold
nanorod
protect
rna
degrad
insid
cell
allow
select
target
cell
use
deliveri
biocompat
gold
nanorod
nanoplex
demonstr
innat
immun
activ
type
influenza
viru
chakravarthi
et
al
human
respiratori
bronchial
epitheli
cell
nanoplex
contain
singl
strand
rna
molecul
activ
retino
acidinduc
gene
pathogen
recognit
pathway
result
increas
express
ifn
interferon
ifnstimul
gene
eg
pkr
result
decreas
replic
influenza
virus
novelti
approach
rna
virus
share
common
hostrespons
immun
pathway
enhanc
host
immun
respons
reduc
ongo
viral
resist
gener
mutat
diseas
could
effect
target
new
approach
includ
virus
suscept
innat
immun
respons
trigger
ifn
anim
studi
start
base
vitro
result
evalu
biocompat
nanoplex
uniqu
antivir
treatment
season
pandem
influenza
virus
warrant
laboratori
test
perman
nanoco
laamscienc
inc
show
coat
kill
influenza
virus
vaccinia
virus
caus
rash
fever
head
bodi
ach
technolog
may
enabl
one
protect
oneself
virtual
virus
bacteria
simpli
expos
surfac
light
mass
transit
railway
mtr
corpor
run
hong
kong
subway
announc
nano
silvertitanium
dioxid
coat
nstdc
nontox
disinfect
appli
surfac
passeng
commonli
touch
enhanc
hygien
level
mtr
station
train
coat
manufactur
use
nanotechnolog
maxim
coverag
effect
nstdc
develop
japan
nstdc
certifi
effect
kill
wide
rang
bacteria
virus
mold
includ
influenza
viru
use
hospit
offic
home
japan
nstdc
main
compon
titanium
dioxid
approv
use
food
fda
public
health
municip
servic
ordin
hong
kong
nanoviricid
nanoviricid
inc
polymer
micel
act
nanomedicin
destroy
virus
defin
nanoviricid
inc
nanoviricid
polymer
singl
chemic
chain
coval
attach
ligand
specifi
viru
target
antivir
spectrum
drug
determin
specif
set
ligand
attach
chain
addit
function
import
aspect
inher
chemistri
nanoviricid
design
seek
specif
viru
type
attach
viru
particl
engulf
coat
viru
particl
therebi
neutral
viru
infect
destabil
possibl
dismantl
viru
particl
option
may
also
made
capabl
attack
viral
genom
therebi
destroy
viru
complet
activ
pharmaceut
ingredi
option
hidden
core
nanoviricid
missil
contrast
approach
micel
recogn
bind
one
type
bind
site
viru
system
enabl
design
drug
bind
one
type
site
current
mani
three
differ
site
viru
highli
effect
attack
nanoviricid
inc
term
multispecif
target
drug
goe
much
block
bind
site
viru
base
materi
special
design
polymer
micel
materi
disassembl
hiv
particl
thu
coat
viru
particl
loosen
viru
particl
weaken
viru
particl
even
fall
apart
uncoat
provid
therapeut
benefit
nanoviricid
plan
enhanc
viral
disassembl
capabl
attach
special
design
molecular
chisel
micel
coat
viru
particl
attach
molecular
chisel
go
work
liter
insert
viru
coat
specif
vulner
point
pri
apart
coat
protein
viru
particl
fall
apart
readili
mechan
action
nanoviricid
depict
schemat
fig
nanoviricid
compar
current
approach
viral
diseas
seldom
cur
advantag
includ
follow
specif
target
viru
metabol
advers
effect
host
biolog
efficaci
nanoviricid
drug
may
sever
order
magnitud
better
usual
chemic
drug
may
limit
potenti
mutant
gener
also
key
aspect
design
nanoviricid
expect
lead
minim
mutant
gener
nanoviricid
safe
uniqu
design
fact
design
biodegrad
within
bodi
new
technolog
enabl
rapid
drug
develop
emerg
viru
would
import
global
biosecur
natur
well
manmad
bioterror
situat
possibl
develop
research
drug
novel
lifethreaten
viral
diseas
within
week
infect
found
ie
soon
antibodi
anim
sourc
avail
possibl
make
singl
nanoviricid
drug
respond
sever
viral
threat
use
target
ligand
desir
set
virus
construct
drug
possibl
tune
specif
rang
spectrum
nanoviricid
drug
within
viru
type
subtyp
strain
appropri
choic
target
ligand
safeti
nanoviricid
drug
proven
specif
attack
viru
host
target
approach
includ
influenza
hiv
hcv
rabi
virus
nanoviricid
drug
candid
current
preclin
studi
clinic
trial
plan
initi
inject
product
effect
altern
rout
administr
nasal
spray
bronchial
aerosol
also
develop
nanoviricid
inc
develop
evalu
nanoviricid
influenza
avian
flu
efficaci
safeti
nanoviricid
design
polymer
surfact
micel
coval
attach
ligand
bind
influenza
viru
conserv
site
current
drug
candid
effect
differ
strain
direct
result
use
conserv
bind
strategi
like
use
zanamivir
howev
flucid
direct
bind
ha
rather
inhibit
neuraminidas
bind
ha
follow
put
engulf
viru
particl
lead
viral
load
reduct
therapeut
benefit
preclin
studi
shown
flucid
antibodi
complet
task
encapsul
possibl
dismantl
viru
rather
mere
tag
immun
system
foreign
particl
mous
model
common
murineadapt
influenza
would
requir
eight
time
greater
dosag
oseltamivir
compar
flucid
achiev
surviv
advantag
result
cell
cultur
mdck
pmkc
influenza
bird
flu
strain
clade
clade
drug
candid
shown
high
cpe
inhibit
intraven
prepar
system
administr
develop
readytous
preload
syring
rout
administr
explor
preind
brief
document
flucid
submit
fda
nanocarriermedi
deliveri
sirna
enhanc
efficaci
sirnabas
therapi
hivaid
mishra
et
al
vivo
use
sirna
limit
variou
factor
includ
degrad
rnase
rapid
elimin
endosom
trap
low
cell
permeabl
aqueou
solubl
high
neg
charg
sirna
howev
sever
promis
nanoparticl
includ
liposom
dendrim
develop
sirnamedi
gene
silenc
treatment
nanocarri
improv
specif
minim
toxic
abil
shepherd
sirna
deliveri
toward
specifi
target
site
cross
plasma
membran
silver
nanoparticl
possess
mani
uniqu
properti
make
attract
use
biolog
applic
silver
nanoparticl
use
surfac
coat
prophylaxi
infect
shown
nm
silver
nanoparticl
bactericid
possibl
use
silver
nanoparticl
antivir
agent
explor
silver
nanoparticl
undergo
sizedepend
interact
particl
rang
nm
attach
viru
regular
spatial
arrang
attach
nanoparticl
centertocent
distanc
nanoparticl
fact
expos
sulfurbear
residu
glycoprotein
knob
would
attract
site
nanoparticl
interact
suggest
silver
nanoparticl
interact
viru
via
preferenti
bind
glycoprotein
knob
due
interact
silver
nanoparticl
inhibit
viru
bind
host
cell
demonstr
vitro
silver
nanoparticl
inhibit
prototyp
arenaviru
tacarib
viru
nontox
concentr
effect
inhibit
arenaviru
replic
administ
prior
viral
infect
earli
initi
viru
exposur
speshock
et
al
suggest
mode
action
viral
neutral
silver
nanoparticl
occur
earli
phase
viral
replic
arbutu
biopharma
sirna
lipid
nanoparticl
novel
antivir
drug
treatment
ebola
viru
ev
infect
arbutu
conduct
seri
studi
collabor
us
armi
medic
research
institut
infecti
diseas
demonstr
abil
protect
nonhuman
primat
ev
geisbert
et
al
use
treat
infect
nonhuman
primat
result
complet
protect
otherwis
lethal
dose
zair
ev
associ
period
outbreak
hemorrhag
fever
human
popul
mortal
rate
reach
data
show
potenti
rnai
effect
postexposur
treatment
strategi
peopl
infect
ev
suggest
strategi
might
also
use
treatment
emerg
viral
infect
arbutu
award
million
contract
us
govern
transform
medic
technolog
program
advanc
ind
applic
approv
fda
phase
safeti
trial
drug
start
fda
place
hold
trial
owe
cytokin
releas
partial
relax
allow
use
evinfect
patient
fda
grant
fast
track
design
develop
singlearm
phase
ii
trial
adult
laboratoryconfirm
evd
administr
dose
mgkgday
intraven
infus
adult
patient
sever
evd
shown
improv
surviv
compar
histor
control
dun
et
al
